NCT02602067View on ClinicalTrials.gov

131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Breast NeoplasmHead and Neck NeoplasmSkin NeoplasmRespiratory Tract NeoplasmUrogenital NeoplasmDigestive System NeoplasmPancreatic NeoplasmConnective and Soft Tissue NeoplasmLymphoma, Non-Hodgkin
Interventions
COMBINATION_PRODUCT

131I-Tenatumomab

I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C

Trial Locations (7)

20089

Humanitas Clinical Institute, Rozzano MI

33076

Institut Bergonnie, Bordeaux

34298

Icm Val D'Aurelle, Montpellier

42123

S. Maria Nuova Hospital - Irccs, Reggio Emilia

65126

University of Study of Pisa, Pisa

69373

Centre Leon Berard, Lyon

80131

"Istituto Nazionale Dei Tumori Irccs - Fondazione G. Pascale", Naples

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

sigma-tau i.f.r. S.p.A.

INDUSTRY

NCT02602067 - 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients | Biotech Hunter | Biotech Hunter